Document is current
Any future updates will be listed below
-
Authors
Giunta, Emilio Francesco https://orcid.org/0000-0002-5383-4469
Caroli, Paola
Scarpi, Emanuela
Altavilla, Amelia
Rossetti, Virginia
Marini, Irene
Celli, Monica
Casadei, Chiara
Lolli, Cristian
Schepisi, Giuseppe
Bleve, Sara
Brighi, Nicole
Cursano, Maria Concetta
Paganelli, Giovanni
Matteucci, Federica
De Giorgi, Ugo
-
Funding
Funding for this research was provided by:
Ricerca Corrente by the Italian Ministry of Health. (Ricerca Corrente by the Italian Ministry of Health.)
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 12 August 2024
First Online: 29 August 2024
Declarations
:
: This prospective study was approved by the Institutional Review Board and Ethics Committee of IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy (protocol code: IRST B073). The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference of Harmonization A written informed consent was obtained from all the enrolled patients.
: All patients participating in the present study and the authors consent to publish and print the information contained in this article.
: Financial interests: EFG reports honoraria from Astellas and travel support from Janssen-Cilag and Bayer. CL reports honoraria for advisory boards or speaker fees from Ipsen, BMS and MSD. GS reports honoraria from Bayer, BMS and Ipsen. NB reports travel support from Ipsen, Novartis, Janssen-Cilag, Pfizer and Advanced Accelerator Applications, speaker honoraria from BMS. MCC reports travel accommodation from Ipsen. UDG reports honoraria for advisory boards or speaker fees from Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. The other authors do not report any conflicts of interest.
